Desmethyl cariprazine prodrug - Abbvie
Alternative Names: ABBV-932Latest Information Update: 26 Jul 2024
At a glance
- Originator AbbVie
- Class Anxiolytics; Mood stabilisers; Small molecules
- Mechanism of Action Dopamine D3 receptor partial agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Bipolar disorders; Generalised anxiety disorder
Most Recent Events
- 31 May 2024 AbbVie completes the phase I trial in Generalised anxiety disorders (In volunteers) in USA (PO) (NCT05738850)
- 12 Mar 2024 AbbVie plans a phase I trial in healthy adult volunteers in United Kingdom in May 2024 (PO, Capsules) (NCT06300580)
- 31 Aug 2023 Phase-I clinical trials in Bipolar disorders in USA (PO) (NCT06024239)